RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of
Cytokines
IVT-mRNA
Immunogenicity
Whole blood assay
cmRNA
Journal
Bio-protocol
ISSN: 2331-8325
Titre abrégé: Bio Protoc
Pays: United States
ID NLM: 101635102
Informations de publication
Date de publication:
20 Dec 2020
20 Dec 2020
Historique:
received:
02
07
2020
revised:
24
09
2020
accepted:
28
09
2020
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
The mRNA therapeutics is a new class of medicine to treat many various diseases. However,
Identifiants
pubmed: 33855105
doi: 10.21769/BioProtoc.3850
pii: e3850
pmc: PMC8032499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e3850Informations de copyright
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.
Déclaration de conflit d'intérêts
Competing interestsMSDK holds a patent on RNA modification licensed to the biopharmaceutical company, Ethris GmbH (EP2459231B1), and is listed as main inventor on a patent application related to Nuclease encoding modified mRNA. MSDK, AH, and JSA hold a European patent on delivery of chemically modified mRNA complexed to nanoparticles for the treatment of pulmonary diseases (EP3398963A1).
Références
Nucleic Acids Res. 2011 Nov;39(21):e142
pubmed: 21890902
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
Mol Cell Pediatr. 2015 Dec;2(1):11
pubmed: 26589812
Mol Ther Nucleic Acids. 2018 Sep 7;12:530-542
pubmed: 30195789